Roche licenses baloxavir marboxil to the Medicines Patent Pool for 129 low- and middle-income countries

The licence’s country list is built around low- and middle-income countries and Sub-Saharan African markets are within it; the MPP licence page states the instrument and the 129-country scope, and the MPP sublicences that follow are signed with African manufacturers (recorded separately).


Coverage: The Meridian legal market record (editorial).

The licence's country list is built around low- and middle-income countries and Sub-Saharan African markets are within it; the MPP licence page states the instrument and the 129-country scope, and the MPP sublicences that follow are signed with African manufacturers (recorded separately).

Record ID TX-AFR-2026-0020
Record type Commercial IP transaction
Transaction type Patent licence, Non-exclusive licence, Technology transfer, In-licensing
IP rights patent, know-how, regulatory data
Status Signed
Qualifying date 2026-05 (month precision)
Sector Life sciences · Pharmaceuticals – antivirals
African markets Multi-jurisdictional
Licensed territory 129 low- and middle-income countries, subject to local regulatory authorisation.
Disclosed value Not disclosed in the sources reviewed.
Evidence Primary source, independently corroborated · 2 source(s)
Last verified 2026-10-25

Parties

  • Medicines Patent Pool Foundation (Switzerland): licensee, sublicensor
  • F. Hoffmann-La Roche (Switzerland): licensor

Key terms

  • Interest: non-exclusive licence (with right to sublicense); Exclusivity: non-exclusive; Territorial scope: 129 low- and middle-income countries

Sources

  1. Baloxavir marboxil licence (Roche / MPP), Medicines Patent Pool, 2026-05-15
  2. Uganda's Qcil Wins Licence to Develop Generic Influenza Treatment, ChimpReports, 2026-09-25

Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.